Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc., formerly Cytoclonal Pharmaceuticals Inc.). The company is a Delaware corporation classified as a shell company and a nonaccelerated filer. eXegenics has terminated all research and development activities and eliminated scientific staff. Management is currently focused on redeploying residual assets and identifying new business opportunities.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2006 | Six Months Ended June 30, 2006 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss (Common Shareholders) | $(68,000) | $(350,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.00) | $(0.02) |
| Cash and Cash Equivalents | $8,805,000 (Ending Balance) | $8,805,000 (Ending Balance) |
| Net Cash Used in Operating Activities | $(46,000) (Q2 only) | $(96,000) (Six Months) |
| Total Liabilities | $262,000 | $262,000 |
| Preferred Stock Dividends | $0 | $(238,000) |
Material Changes vs. Prior Period
- Operating Expenses: General and administrative expenses decreased significantly. For the three months ended June 30, 2006, expenses were $170,000 compared to $484,000 in the prior year period (a 65% decrease). For the six-month period, expenses were $359,000 compared to $815,000 (a 56% decrease). This reduction is primarily due to lower officer salaries, reduced insurance premiums, and the absence of a large allowance recorded in 2005 for a subscription receivable.
- Interest Income: Other income, primarily interest, increased to $102,000 for the quarter (from $50,000) and $247,000 for the six months (from $90,000), attributed to increased interest rates on cash deposits.
- Net Loss: Net loss attributable to common shareholders improved to $(68,000) for the quarter and $(350,000) for the six months, compared to $(434,000) and $(959,000) in the respective prior year periods.
Outlook, Risks, and Contingencies
- Strategic Direction: The company has no active revenue-generating operations. The Board has established a committee to study strategic direction and redeploy assets. There is no specific financial guidance provided for future periods.
- Legal Proceedings: A jury ruled against the company in a case brought by former employee Dr. Abdel Hakim Labidi, awarding $600,000 for conversion of biological materials. The company has recorded a provision of $250,000. The final amount due is estimated between $250,000 and $750,000, pending a court decision on attorney fees and interest.
- Subscription Receivable: A note receivable of $300,000 plus interest from a former CEO (Dr. Ronald Goode) is in default. The balance is presented net of a reserve, equal to the value of underlying collateral.
- Accounting Changes: The company adopted SFAS No. 123R on January 1, 2006, requiring the recognition of compensation expense for share-based payments. This resulted in approximately $2,000 of expense in the second quarter of 2006.
Investor Verification Checklist
- Verify the status of the legal judgment against Dr. Labidi and the potential for additional costs beyond the $250,000 provision.
- Confirm the collectability of the subscription receivable from Dr. Goode and the value of the underlying collateral.
- Monitor the company's cash burn rate ($96,000 used in operations over six months) against its cash balance of $8.8 million to assess runway.
- Review the Board's progress in identifying new business opportunities or asset redeployment strategies, as the company currently has no revenue.
- Check for any updates on the preferred stock dividend obligations ($238,000 paid in the first six months of 2006).